Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $8.0, a ...

Recursion is a key feature of language. It enables us to build elaborate sentences from simple ones. Take the sentence “The mouse the cat chased ran.” ...

The other AI biotech company that Recursion is merging with before early 2025, Exscientia, counts Merck, Sanofi, and Bristol Myers Squibb among its collaborators. Many of the other major players ...

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More ...

Recursion Pharmaceuticals (RXRX) closed at $6.67 in the latest trading session, marking a -1.91% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.28% ...

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC ...

Recursion also announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-4539, a potential best-in ...

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More Jan. 07, 2025 9:15 ...